China Releases More Health-Reform Guidelines, But Drug System Delayed
This article was originally published in PharmAsia News
Executive Summary
China's State Council issued additional guidelines of its long-delayed health care reform plan, including a delay in the release of a basic-drugs catalogue until the end of the year. The catalogue is part of a system for pharmaceuticals, also delayed until the end of the year, intended to be implemented in 30 percent of the nation's community clinics and county-level clinics. It already had been disclosed the catalogue drugs would be produced and distributed under government control. The drugs would be covered by medical insurance, requiring another special administration to be established. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.